Gromova, O A, Torshin, I Y, Chuchalin, A G et al. · Terapevticheskii arkhiv · 2022 · DOI
This review examines human placenta hydrolysates (HPH)—processed extracts from human placental tissue—and their potential therapeutic effects on various conditions including chronic fatigue syndrome. The authors summarize over 5,000 published studies showing that HPH may work by stimulating the body's natural healing and regenerative abilities. The review discusses HPH's reported benefits for liver disease, skin conditions, viral infections, and fatigue-related disorders.
For ME/CFS patients and researchers, this review is notable because it explicitly addresses chronic fatigue syndrome as one application of HPH and proposes biological mechanisms (regeneration, immunomodulation) that could theoretically benefit energy metabolism and recovery. However, the evidence quality for ME/CFS specifically remains unclear without access to the detailed claims within the full text.
This narrative review does not provide definitive proof of HPH efficacy for ME/CFS—it synthesizes existing literature rather than presenting new clinical trial data or mechanistic evidence specific to ME/CFS. The review does not establish causal mechanisms, controlled efficacy comparisons, or safety profiles specific to ME/CFS populations. No information is provided about study quality, effect sizes, or potential publication bias among the 5,000+ publications cited.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →